SRDX

Surmodics, Inc. (SRDX) | Rumor.io

Surmodics

SRDX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SRDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 17

The FTC has announced that it does not intend to appeal the denial of an injunction, allowing the acquisition of Surmodics by GTCR to potentially move forward.
The temporary restraining order blocking the sale is set to expire today, paving the way for the deal to be completed unless further legal roadblocks appear.
Surmodics' stock price has risen to a new 52-week high, with the company's ticker, SRDX, trading at $42.85 and a volume of 7.4 million shares.

Generated by AI

Sentiment

Of the messages about SRDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.91% +46.79
Bearish	—	—	—	9.09% -46.79

Nov 11

$SRDX has broken out with bullish vibes, with a surge in volume and RSI pushing into overbought territory, indicating momentum building.
The company's acquisition by GTCR is expected to be completed, with a deal valued at $627 million offering shareholders $43 per share in cash, a major win for medtech.
The Pounce thrombectomy platform is gaining traction in real-world data, contributing to the company's soaring stock price and renewed acquisition buzz.

Generated by AI

Topics

Of the messages about SRDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	69.11%
Controversies	—	—	—	28.01%
Earnings	—	—	—	0.26%
Macro	—	—	—	0%
Technical Analysis	—	—	—	2.62%

Earnings· Nov 8

SRDX reports earnings tomorrow with an estimated +0.04 EPS and -0.01M Revs according to Estimize Consensus.
The company's expected earnings beat the Wall Street Consensus.
The earnings report is expected to be released before the open.

Announcements· May 29

Surmodics, Inc. (SRDX) has agreed to be acquired by affiliates of private equity firm GTCR for $43 per share in cash, valuing the company at approximately $627 million.
The acquisition represents a 22.51% premium over SRDX's closing price and is expected to close in the second half of 2024, subject to shareholder and regulatory approval.
Upon completion of the transaction, SRDX will be a privately held company and its common stock will no longer be listed on the Nasdaq Stock Exchange.

Generated by AI

Community

Of the messages about SRDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	38.54%
Newcomers	—	—	—	61.46%

Regulars· May 29

Surmodics, Inc. has entered into a definitive agreement to be acquired by private equity firm GTCR for $43.00 per share in cash, representing an approximate equity value of $627 million.
The acquisition is expected to be completed soon, with Surmodics' shareholders set to receive a significant payout.
The deal marks a major development for Surmodics, Inc. as it transitions to a private company, and regulars are closely watching the implications for the company's future.

Newcomers· Nov 11

The court's decision to deny the FTC's injunction has cleared a major hurdle for the merger between Surmodics and GTCR, with the deal now expected to proceed.
The acquisition by GTCR is valued at approximately $627 million, and Surmodics' shares have surged over 50% in response.
The merger has been seen as a major opportunity for Surmodics, with the company's Pounce thrombectomy platform gaining traction in real-world data and heavy volume being seen in the stock.

Generated by AI

Also Discussed

Investors talking about SRDX also mention

#	Name	Attention
1	The Toro CompanyTTC	0%0
2	AXNX - Axonics, Inc.	——
3	ABMD - Abiomed, Inc.	——
4	SGRP - SPAR Group, Inc.	——
5	Glaukos CorporationGKOS	0%+0
6	Baxter International IncBAX	0%0
7	OraSure Technologies Inc.OSUR	0%new
8	DLH Holdings Corp.DLHC	0%0
9	RVNC - Revance Therapeutics, Inc.	——
10	LivaNova PLCLIVN	0%0

Surmodics, Inc.

Location

Social

What share of all stock conversation is about SRDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 17

The FTC has announced that it does not intend to appeal the denial of an injunction, allowing the acquisition of Surmodics by GTCR to potentially move forward.
The temporary restraining order blocking the sale is set to expire today, paving the way for the deal to be completed unless further legal roadblocks appear.
Surmodics' stock price has risen to a new 52-week high, with the company's ticker, SRDX, trading at $42.85 and a volume of 7.4 million shares.

Generated by AI

Sentiment

Of the messages about SRDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.91% +46.79
Bearish	—	—	—	9.09% -46.79

Nov 11

$SRDX has broken out with bullish vibes, with a surge in volume and RSI pushing into overbought territory, indicating momentum building.
The company's acquisition by GTCR is expected to be completed, with a deal valued at $627 million offering shareholders $43 per share in cash, a major win for medtech.
The Pounce thrombectomy platform is gaining traction in real-world data, contributing to the company's soaring stock price and renewed acquisition buzz.

Generated by AI

Topics

Of the messages about SRDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	69.11%
Controversies	—	—	—	28.01%
Earnings	—	—	—	0.26%
Macro	—	—	—	0%
Technical Analysis	—	—	—	2.62%

Earnings· Nov 8

SRDX reports earnings tomorrow with an estimated +0.04 EPS and -0.01M Revs according to Estimize Consensus.
The company's expected earnings beat the Wall Street Consensus.
The earnings report is expected to be released before the open.

Announcements· May 29

Surmodics, Inc. (SRDX) has agreed to be acquired by affiliates of private equity firm GTCR for $43 per share in cash, valuing the company at approximately $627 million.
The acquisition represents a 22.51% premium over SRDX's closing price and is expected to close in the second half of 2024, subject to shareholder and regulatory approval.
Upon completion of the transaction, SRDX will be a privately held company and its common stock will no longer be listed on the Nasdaq Stock Exchange.

Generated by AI

Community

Of the messages about SRDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	38.54%
Newcomers	—	—	—	61.46%

Regulars· May 29

Surmodics, Inc. has entered into a definitive agreement to be acquired by private equity firm GTCR for $43.00 per share in cash, representing an approximate equity value of $627 million.
The acquisition is expected to be completed soon, with Surmodics' shareholders set to receive a significant payout.
The deal marks a major development for Surmodics, Inc. as it transitions to a private company, and regulars are closely watching the implications for the company's future.

Newcomers· Nov 11

The court's decision to deny the FTC's injunction has cleared a major hurdle for the merger between Surmodics and GTCR, with the deal now expected to proceed.
The acquisition by GTCR is valued at approximately $627 million, and Surmodics' shares have surged over 50% in response.
The merger has been seen as a major opportunity for Surmodics, with the company's Pounce thrombectomy platform gaining traction in real-world data and heavy volume being seen in the stock.

Generated by AI

Surmodics

Social

Nov 17

Sentiment

Nov 11

Topics

Earnings· Nov 8

Announcements· May 29

Community

Regulars· May 29

Newcomers· Nov 11

Also Discussed

Surmodics, Inc.

Company Information

Location

Also Discussed

Social

Nov 17

Sentiment

Nov 11

Topics

Earnings· Nov 8

Announcements· May 29

Community

Regulars· May 29

Newcomers· Nov 11